Proteome Sciences Company Description

Proteome Sciences plc provides contract research services for the identification, validation, and application of protein biomarkers in the United States, the United Kingdom, European Union, and internationally.

The company offers TMT LC-MS2, a standard method for analyzing cells and tissues when no phosphopeptide enrichment is required; TMT LC-MS3, a standard method for biomarker discovery in plasma and other samples where quantitative accuracy is a factor; SysQuant, provides an analysis of protein activity across regulatory and signaling pathways; and TMTcalibrator, analyzes where diseased or treated tissue can be analyzed in parallel with peripheral fluids.

It also provides top 14 and top 65 super depletion of proteins from serum and plasma; selective reaction monitoring (SRM) and parallel reaction monitoring (PRM) based biomarker assay development; SRM assay, a targeted mass spectrometry assay format for the routine measurement of biomarkers; and TMT SRM, a targeted assay format that enables the rapid validation of biomarker candidates.

The company serves its products to pharmaceutical and biotechnology companies, and academic research institutes.

The company was incorporated in 1993 and is based in Cobham, the United Kingdom.

Proteome Sciences plc

Country	United Kingdom
Founded	1993
Industry	Diagnostics & Research
Sector	Healthcare
Employees	36
CEO	Mariola Sohngen

Contact Details

Address: Coveham House Cobham, KT11 3EP United Kingdom
Phone	44 20 7043 2116
Website	proteomics.com

Stock Details

Ticker Symbol	PMSNF
Exchange	OTCMKTS
Fiscal Year	January - December
Reporting Currency	GBP
ISIN Number	GB0003104196
SIC Code	8731

Key Executives

Name	Position
Christopher Donovan James Pearce Dip., MSI	Executive Chairman
Dr. Ian Hugo Pike	Chief Scientific Officer and Executive Director
Richard Paul Dennis	Chief Commercial Officer and Executive Director
Victoria Joanna Birse	Company Secretary